[Skip to Content]
[Skip to Content Landing]
Views 176
Citations 0
Viewpoint
November 8, 2017

The Imminent Demise of Cardiovascular Drug Development

Author Affiliations
  • 1Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Texas
JAMA Cardiol. Published online November 8, 2017. doi:10.1001/jamacardio.2017.3753

The development of new cardiovascular drugs is at its deepest nadir in decades.1 Major pharmaceutical companies have ended research activities in cardiology,2 and applications to and approvals by the US Food and Drug Administration for new cardiovascular pharmaceuticals have declined dramatically even as innovations in other therapeutic areas have soared.1

First Page Preview View Large
First page PDF preview
First page PDF preview
×